HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Erb, D. Articles by Nabi, H. PubMed Articles by Erb, D. Articles by Nabi, H.

Predictive values of Miraluma scintimammography in patients with localized breast abnormalities and intermediate risks for carcinoma

¹ Nuclear Medicine, University at Buffalo, Buffalo, New York

2118

Objectives: The purpose of this study is to assess the negative and positive predictive values (NPV and PPV) of Miraluma scintimammography in female patients(pts) with palpable or non-palpable breast lesions and intermediate (Bi Rads 3) risks for carcinoma by mammography.

Methods: A total of 60 female pts were referred for Miraluma imaging were evaluated. 31 had palpable masses and 27 had non-palpable mammographic abnormalities (Bi Rad 3). One pt had known Paget’s disease and one presented with a bloody discharge from the nipple. All pts were scanned in multiple views, including prone-dependent lateral views following IV administration of 20-25 mCi of Tc-99m sestamibi in the arm opposite the suspected lesions. Miraluma scintiscans were interpreted by an experienced nuclear physician with knowledge of pertinent patient information. Results of Miraluma scans were compared to follow-up data (mammograms, physical examination, biopsy). Mean length of follow-up was 9-37 months.

Results: Only two of 60 pts had breast cancers, one missed by Miraluma. Of the 58 pts with benign findings, Miraluma scans were true negative in 52 (specificity 90%, NPV 98%), and false positive in 6 pts with active fibrocystic disease (scans showed a diffuse pattern). None of the false positive pts required surgical intervention. Specificity and negative predictive values were slightly higher in patients with palpable lesions than in patients with non-palpable disease (94% and 100%, versus 83% and 95%), although the difference did not reach statistical significance.

Conclusions: Miraluma scintimammography is a useful tool in patients with intermediate risks for breast cancers. The high specificity and negative predictive value could reduce the need for follow-up tests, and alleviate the patient’s emotional burden.

This Article Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Erb, D. Articles by Nabi, H. PubMed Articles by Erb, D. Articles by Nabi, H.